Log In
BCIQ
Print this Print this
 

HuMax-IL8 (formerly HuMax-Inflam/MDX-018)

  Manage Alerts
Collapse Summary General Information
Company Genmab A/S
DescriptionHuman IgG1, kappa antibody targeting IL-8 (CXCL8)
Molecular Target Interleukin-8 (IL-8) (CXCL8)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$520.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/01/2016

$520.0M

Undisclosed

Undisclosed

06/04/2012

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today